NR 565 PHARMACOLOGY MIDTERM EXAM QUESTIONS & ANSWERS 2026-2027 | COMPREHENSIV… EXAM
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 565 Pharmacology Midterm
Exam Questions & Answers 2026-
2027 | Comprehensive Review |
Verified Study Guide (Rationales)
Verified Answers Exam Ready With Rationales
69 QUESTIONS
DOCUMENT OVERVIEW
This document contains 69 verified pharmacology questions, each paired with the correct answer and
detailed rationales, offering a comprehensive review of key concepts. It serves as an essential resource for
students preparing for exams, enhancing their understanding of pharmacological principles. The structured
format allows for efficient study and review, making it suitable for certification preparation and course
reinforcement.
CONTENTS
01 CYP Enzymes Q1–Q4
02 Controlled Substances Q5–Q10
03 Drug Development Phases Q11–Q16
04 Adrenergic Pharmacology Q17–Q28
05 Cholinergic Pharmacology Q29–Q33
06 Anticonvulsants and Mood Stabilizers Q34–Q44
07 Psychotropic Medications Q45–Q58
Page 1
, 08 Assessment and Treatment Algorithms Q59–Q69
E XA M Q U EST I O N S
Q1 QUESTION 1 OF 69
CYP2D6
CORRECT ANSWER
Need to increase doses of SSRI, beta blockers etc.
Codeine can be deadly
RATIONALE
CYP2D6 is a key enzyme in drug metabolism, influencing the efficacy and safety of SSRIs and beta-blockers; individuals with altered CYP2D6
activity may require increased doses for therapeutic effect. Additionally, this enzyme converts codeine to its active metabolite morphine,
posing a significant risk of overdose in ultra-rapid metabolizers.
Q2 QUESTION 2 OF 69
CYP2C9
CORRECT ANSWER
Decrease warfarin dose
Test for gene VCORC1 mutation
RATIONALE
CYP2C9 polymorphisms significantly influence warfarin metabolism, necessitating dosage adjustments to maintain therapeutic INR levels and
avoid bleeding complications. Testing for VCORC1 mutations further personalizes anticoagulation therapy by identifying patients with altered
sensitivity to warfarin.
Q3 QUESTION 3 OF 69
CYP3A4
CORRECT ANSWER
Decreases elimination
Increase toxicity of Amio
RATIONALE
CYP3A4 is a key enzyme in drug metabolism, and its inhibition can lead to decreased clearance of medications like amiodarone, resulting in
increased plasma levels and potential toxicity. Understanding the role of CYP3A4 in drug interactions is critical for safe pharmacotherapy
management.
Page 2
, Q4 QUESTION 4 OF 69
Anorexiants
CORRECT ANSWER
drugs that suppress the activity of the brain's appetite center, causing reduced food intake
phendimetrazine tartrate, benzphetamine, diethylpropion HCL, phentermine, lorcaserin
RATIONALE
Anorexiants function by modulating neurotransmitter activity in the hypothalamus, specifically targeting the appetite center to decrease
hunger signals and promote weight loss. This pharmacological action is crucial for managing obesity by reducing caloric intake through
effective appetite suppression.
Q5 QUESTION 5 OF 69
Schedule I
CORRECT ANSWER
no accepted medical use in the US it may not be prescribed.
heroin,various opium derivatives,hallucinogenic substances
RATIONALE
Controlled substances classified as Schedule I lack accepted medical use in the United States, indicating they are deemed to have a high
potential for abuse and no accepted therapeutic benefits, which prohibits their prescription. Examples include heroin and hallucinogens,
underscoring the dangers associated with these substances.
Q6 QUESTION 6 OF 69
Schedule II
CORRECT ANSWER
No refills, no telephone orders
Narcotics, Stimulants, Depressants
RATIONALE
Schedule II drugs are classified as having a high potential for abuse and dependence, necessitating strict regulations such as prohibiting refills
and telephone orders to ensure careful monitoring and control. This regulation reflects the principle of minimizing risks associated with
powerful narcotics, stimulants, and depressants in clinical practice.
Q7 QUESTION 7 OF 69
Page 3
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 565 Pharmacology Midterm
Exam Questions & Answers 2026-
2027 | Comprehensive Review |
Verified Study Guide (Rationales)
Verified Answers Exam Ready With Rationales
69 QUESTIONS
DOCUMENT OVERVIEW
This document contains 69 verified pharmacology questions, each paired with the correct answer and
detailed rationales, offering a comprehensive review of key concepts. It serves as an essential resource for
students preparing for exams, enhancing their understanding of pharmacological principles. The structured
format allows for efficient study and review, making it suitable for certification preparation and course
reinforcement.
CONTENTS
01 CYP Enzymes Q1–Q4
02 Controlled Substances Q5–Q10
03 Drug Development Phases Q11–Q16
04 Adrenergic Pharmacology Q17–Q28
05 Cholinergic Pharmacology Q29–Q33
06 Anticonvulsants and Mood Stabilizers Q34–Q44
07 Psychotropic Medications Q45–Q58
Page 1
, 08 Assessment and Treatment Algorithms Q59–Q69
E XA M Q U EST I O N S
Q1 QUESTION 1 OF 69
CYP2D6
CORRECT ANSWER
Need to increase doses of SSRI, beta blockers etc.
Codeine can be deadly
RATIONALE
CYP2D6 is a key enzyme in drug metabolism, influencing the efficacy and safety of SSRIs and beta-blockers; individuals with altered CYP2D6
activity may require increased doses for therapeutic effect. Additionally, this enzyme converts codeine to its active metabolite morphine,
posing a significant risk of overdose in ultra-rapid metabolizers.
Q2 QUESTION 2 OF 69
CYP2C9
CORRECT ANSWER
Decrease warfarin dose
Test for gene VCORC1 mutation
RATIONALE
CYP2C9 polymorphisms significantly influence warfarin metabolism, necessitating dosage adjustments to maintain therapeutic INR levels and
avoid bleeding complications. Testing for VCORC1 mutations further personalizes anticoagulation therapy by identifying patients with altered
sensitivity to warfarin.
Q3 QUESTION 3 OF 69
CYP3A4
CORRECT ANSWER
Decreases elimination
Increase toxicity of Amio
RATIONALE
CYP3A4 is a key enzyme in drug metabolism, and its inhibition can lead to decreased clearance of medications like amiodarone, resulting in
increased plasma levels and potential toxicity. Understanding the role of CYP3A4 in drug interactions is critical for safe pharmacotherapy
management.
Page 2
, Q4 QUESTION 4 OF 69
Anorexiants
CORRECT ANSWER
drugs that suppress the activity of the brain's appetite center, causing reduced food intake
phendimetrazine tartrate, benzphetamine, diethylpropion HCL, phentermine, lorcaserin
RATIONALE
Anorexiants function by modulating neurotransmitter activity in the hypothalamus, specifically targeting the appetite center to decrease
hunger signals and promote weight loss. This pharmacological action is crucial for managing obesity by reducing caloric intake through
effective appetite suppression.
Q5 QUESTION 5 OF 69
Schedule I
CORRECT ANSWER
no accepted medical use in the US it may not be prescribed.
heroin,various opium derivatives,hallucinogenic substances
RATIONALE
Controlled substances classified as Schedule I lack accepted medical use in the United States, indicating they are deemed to have a high
potential for abuse and no accepted therapeutic benefits, which prohibits their prescription. Examples include heroin and hallucinogens,
underscoring the dangers associated with these substances.
Q6 QUESTION 6 OF 69
Schedule II
CORRECT ANSWER
No refills, no telephone orders
Narcotics, Stimulants, Depressants
RATIONALE
Schedule II drugs are classified as having a high potential for abuse and dependence, necessitating strict regulations such as prohibiting refills
and telephone orders to ensure careful monitoring and control. This regulation reflects the principle of minimizing risks associated with
powerful narcotics, stimulants, and depressants in clinical practice.
Q7 QUESTION 7 OF 69
Page 3
